Showing 8121-8130 of 9881 results for "".
- ADCS Acquires Montgomery Dermatology; Catawba Research Enters Partnershiphttps://practicaldermatology.com/news/adcs-acquires-montgomery-dermatology-catawba-research-enters-partnership/2460565/Advanced Dermatology and Cosmetic Surgery (ADCS), the largest dermatology practice in the US, has acquired Dermatology Associates of Montgomery, a leading dermatology practice based in the Southeast. Bundy Group served as exclusive financial advisor to Dr. Steve Maddox, owner of Dermatology
- Optical Coherence Tomography Plus AI Can Quickly and Accurately Monitor Hair Regrowthhttps://practicaldermatology.com/news/optical-coherence-tomography-plus-ai-can-quickly-and-accurately-monitor-hair-regrowth/2460564/Optical coherence tomography plus artificial intelligence methods can accurately and efficiently monitor hair growth therapies, suggests a
- Third RAD Conference Goes Virtual in Decemberhttps://practicaldermatology.com/news/third-rad-conference-goes-virtual-in-december/2460555/With a virtual format, the Third Revolutionizing Atopic Dermatitis (RAD) Conference is slated for December 13-14, 2020. Described by organizers as the first and only global, multidisciplinary conference dedicated to the discussion of evaluation and treatment options for atopi
- Cynosure Launches FlexSure in US and Canadahttps://practicaldermatology.com/news/cynosure-launches-flexsure-device/2460552/Cynosure is launching FlexSure, the latest addition to the TempSure platform, in the US and Canada. FlexSure is a wrappable radiofrequency (RF) applicator for hands-free treatment on all patients and all skin types. With peel-and-sti
- Zilxi from Vyne Therapeutics Now Availablehttps://practicaldermatology.com/news/zilxi-from-vyne-therapeutics-now-available/2460551/Zilxi™ (minocycline) topical foam, 1.5% is now available by prescription for the treatment of inflammatory lesions of rosacea in adults. Zilxi, from Vyne Therapeutics, Inc. is the first minocycline product of any form to be approved by the FDA for use in rosacea, a diverse skin co
- Patients with Chronic Conditions Who Experience Telehealth Rate it Higher than Those Who Have Nothttps://practicaldermatology.com/news/patients-with-chronic-conditions-who-experience-telehealth-rated-it-higher-than-those-who-have-not/2460548/People who have tried telehealth since the onset of COVID-19 have a significantly different perception of its value than those who've not yet experienced a virtual doctor appointment, and they wish to use it again in the future. That’s the finding from a survey from
- Hoth Therapeutics’ HT-003 Inhibits Acne Gene TLR2https://practicaldermatology.com/news/hoth-therapeutics-ht-003-inhibits-acne-gene-tlr2/2460538/Hoth Therapeutics, Inc. completed testing on the ability of HT-003 to block acne pathogenic gene expression in human keratinocytes. Initial data from the first phase of the research reports that toll-like receptor 2 (TLR2) is significantly
- Drumroll, Please...Gwyneth Paltrow Named Global Face of Xeominhttps://practicaldermatology.com/news/gwyneth-paltrow-named-global-face-of-xeomin/2460530/Actress and Goop wellness guru Gwyneth Paltrow is the first global face of Merz Aesthetics' Xeomin. In this role, Paltrow will be sharing details about what she does to look and feel her best, and will ask women to do the same on social media using #DareToSelfCare. “
- Lilly Launches Digital Health Open Innovation Challenge to Help Transform AD Carehttps://practicaldermatology.com/news/lilly-launches-digital-health-open-innovation-challenge-to-help-transform-ad-care/2460529/Eli Lilly and Company is launching an open innovation challenge for individuals and teams across the United States to submit inspiring digital health solutions to help make life better for people living with atopic dermatitis. The challenge, "Transforming Atopic Der
- Remembering 9-11: A Dermatology Perspectivehttps://practicaldermatology.com/news/remembering-9-11-a-dermatology-perspective/2460522/New research takes a close look at dermatologic injuries and chronic skin conditions that have affected survivors and responders during the nearly two decades since the terrorist attacks on September 11, 2001. These chronic illnesses include sarcoidosis, autoimmune disease, ill-defined